Once the crown jewel of China’s biotechnology boom, the Human Papillomavirus (HPV) vaccine market has entered a period of brutal correction. For years, the vaccine was so scarce that mainland residents traveled in droves to Hong Kong, spending thousands of dollars to secure a full course of treatment. This frenzy propelled the market caps of domestic players like Wantai Biological and Zhifei Biological into the hundreds of billions, minting two of China’s wealthiest billionaires in the process.
However, the tide has turned with startling speed. Recent 2025 financial reports reveal a sector in freefall. Wantai Biological posted a net loss of 398 million RMB—its first annual loss since going public—as revenue shrank nearly 19%. Zhifei Biological fared even worse, recording a staggering net loss of over 14.7 billion RMB, the single largest loss among all A-share listed pharmaceutical firms for the year. This financial carnage stems from a fundamental shift from scarcity to saturation.
As vaccination rates among the primary demographic of women aged 9 to 45 climbed from 10% in 2022 to over 27% in 2024, the pool of high-paying, self-funded customers has dwindled. The high-end market, which previously buoyed profits for Zhifei’s imported Merck vaccines, is now nearing exhaustion. Meanwhile, the entry-level 2-valent vaccine market has devolved into a cutthroat 'price war' that has decimated margins across the board.
Government intervention has accelerated this decline. To protect public health, Beijing has begun incorporating HPV vaccines into national immunization programs. While this ensures broad coverage, it forces manufacturers into a 'volume for price' trade-off. Recent government procurement tenders for 2-valent vaccines have seen prices collapse from over 300 RMB per dose to just 27.5 RMB—a 90% drop that essentially commoditizes what was once a premium medical product.
Inventory management has become a nightmare for these firms. HPV vaccines have a relatively short shelf life of 36 months, and the sudden drop in demand has led to massive write-offs. Zhifei was forced to book over 13.6 billion RMB in inventory impairment charges, leading to a renegotiation of its supply agreement with Merck. The days of guaranteed multi-billion-dollar procurement contracts are over, replaced by a cautious, rolling purchase model based on actual demand.
Efforts to find a 'second growth curve' through the male market or overseas expansion have so far yielded lackluster results. Although 9-valent vaccines were recently approved for male use in China, a lack of awareness and narrow age eligibility have limited uptake. Internationally, the complexity of local health policies and regulatory hurdles mean that overseas revenue still accounts for less than 1% of total sales for many of these companies, leaving them trapped in a hyper-competitive domestic landscape.